R & d- medical: aids research (management/support)
Ended Awarded Last action
- Contract number
- 75N93019F00131
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,857,610
Award facts
- Opportunity
-
- NIHAI2015035 Solicitation number
- Contract value 100% obligated
- $2,857,610.47 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$2,639,247 | |
| Other Administrative Action | $0 | |
| Original award | $5,496,857 |
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL) for R&D and medical support services related to AIDS research. The contract has a ceiling value of $2,857,610.47 and a period of performance through August 29, 2024. This award is not associated with a set-aside program.
ABL, a foreign-owned, for-profit manufacturer of goods, provides a wide range of preclinical and clinical development services to support infectious disease research and product development initiatives for government agencies, academic institutions, and industry clients. Through this contract, ABL will likely contribute its expertise in areas such as biologics manufacturing, testing, storage, shipping, and quality assurance to support NIAID's efforts to advance the development of medical countermeasures for HIV/AIDS and other infectious diseases. ABL has previously collaborated with NIAID, the National Cancer Institute (NCI), and the National Institute of Neurological Disorders and Stroke (NINDS) on various grant-funded projects involving vaccine development, immunology studies, and toxicology research.
Quick answers
Who was awarded contract 75N93019F00131?
75N93019F00131 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 30, 2019.
How much is contract 75N93019F00131 worth?
The government has obligated $2,857,610 on 75N93019F00131.
Is contract 75N93019F00131 an order under another contract?
Yes. 75N93019F00131 is a delivery order under HHSN272201700010I, an indefinite delivery contract.
Was contract 75N93019F00131 competed?
The extent of competition for 75N93019F00131 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award